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Development and homeostasis of the cardio-
vascular system require intimate interactions
between endothelial and smooth muscle cells,
which form a seamless circulatory network.
We show that histone deacetylase 7 (HDAC7)
is specifically expressed in the vascular endo-
thelium during early embryogenesis, where it
maintains vascular integrity by repressing the
expression of matrix metalloproteinase (MMP)
10, a secreted endoproteinase that degrades
the extracellular matrix. Disruption of the
HDAC7 gene in mice results in embryonic le-
thality due to a failure in endothelial cell-cell ad-
hesion and consequent dilatation and rupture
of blood vessels. HDAC7 represses MMP10
gene transcription by associating with myocyte
enhancer factor-2 (MEF2), a direct activator of
MMP10 transcription and essential regulator
of blood vessel development. These findings
reveal an unexpected and specific role for
HDAC7 in the maintenance of vascular integrity
and have important implications for under-
standing the processes of angiogenesis and
vascular remodeling during cardiovascular de-
velopment and disease.
INTRODUCTION
Changes in histone acetylation alter chromatin structure
and serve as a key mechanism for the control of gene
expression (Jenuwein and Allis, 2001). Histone acetyl-
transferases (HATs) stimulate transcription by acetylating
nucleosomal histones, which relaxes chromatin structure
and facilitates recruitment of transcription factors to
DNA target sequences. The stimulatory effect of HATs
on gene expression is counteracted by histone deacety-
lases (HDACs), which remove acetyl groups from histonesand promote chromatin condensation with consequent
transcriptional repression.
Mammalian HDACs can be classified based on their
structure and homology to Saccharomyces cerevisiae
HDACs (Grozinger and Schreiber, 2002). Class I HDACs
(HDAC1, 2, 3, 8, and 11), which are ubiquitously ex-
pressed, are homologous to yeast RPD3. Class II HDACs
(HDAC4, 5, 7, and 9) share homology with yeast HDA1 and
display tissue-restricted expression patterns. Class II
HDACs contain an amino-terminal extension that interacts
with other transcriptional cofactors and confers respon-
siveness to extracellular signals (Verdin et al., 2003). Phos-
phorylation of the amino termini of class II HDACs by
calcium/calmodulin-dependent kinase (CaMK) and pro-
tein kinase D (PKD) creates docking sites for the 14-3-3
family of chaperone proteins, which promote shuttling of
these HDACs from the nucleus to the cytoplasm, thereby
derepressing HDAC target genes (McKinsey et al., 2000a,
2000b; Vega et al., 2004a).
Class II HDACs appear to be dedicated to the control of
tissue growth and development. HDAC5 and HDAC9 act
as negative regulators of cardiac growth. Mutant mice
lacking either of these HDACs develop extremely enlarged
hearts in response to pathological signals (Chang et al.,
2004b; Zhang et al., 2002). Conversely, mutants of HDAC5
and HDAC9 lacking the regulatory phosphorylation sites
prevent cardiomyocyte growth. Consistent with these
observations, HDAC5 and HDAC9 associate with and re-
press the activity of myocyte enhancer factor-2 (MEF2),
a MADS-box transcription factor involved in muscle
growth and development (McKinsey et al., 2000a, 2000b;
Zhang et al., 2002).
HDAC4 is expressed in prehypertrophic chondrocytes
of the developing skeleton and determines the timing
and extent of endochondral bone formation (Vega et al.,
2004b). Mice homozygous for an HDAC4mutation exhibit
lethal ossification of endochondral cartilage due to ec-
topic hypertrophy of chondrocytes, whereas ectopic ex-
pression of HDAC4 in chondrocytes inhibits hypertrophic
growth and differentiation.
In the present study, we generated mice lacking
HDAC7, the last of the class II HDACs to be analyzed
in vivo. Remarkably, HDAC7 null mice die during midges-
tation from vascular dilatation and rupture caused by loss
of adhesion between endothelial cells (ECs). Consistent
with this phenotype, HDAC7 is expressed specifically in
the developing vascular endothelium, where it represses
the expression of matrix metalloproteinase 10 (MMP10),
a secreted endoproteinase that degrades the extracellular
matrix and perturbs vascular integrity (Saunders et al.,
2005). In HDAC7 mutant embryos, MMP10 expression is
dramatically upregulated in the vascular endothelium,
and its antagonist, tissue inhibitor of metalloproteinase 1
(TIMP1), is downregulated. HDAC7 represses the pro-
moter of the MMP10 gene by association with MEF2, a
direct activator of MMP10 transcription. These findings
reveal an unexpected and specific role for HDAC7 in the
maintenance of vascular integrity and have important
implications for understanding the mechanisms of angio-
genesis and vascular remodeling during cardiovascular
development and disease.
RESULTS
Generation of HDAC7 Mutant Mice
To explore the functions of HDAC7 in vivo, we inactivated
the mouse HDAC7 gene by homologous recombination in
embryonic stem (ES) cells and generated HDAC7 mutant
mice. The targeted mutation deleted exons 2 to 5, which
encode residues 1–130 that encompass theMEF2 binding
domain of the protein. Themutation also introduced a pro-
moter-less nuclear b-galactosidase protein coding region
inframe with the initiation codon of the HDAC7 gene
(Figure 1A). Targeting ofHDAC7 in ES cells was confirmed
by Southern blot analysis (Figure 1B).
Mice heterozygous for the HDAC7 mutation were via-
ble, fertile, and phenotypically normal. Heterozygote inter-
crosses in the isogenic SvEv129 background, as well as in
the SvEv129/C57BL6 mixed background, failed to yield
any live HDAC7 homozygous mutant pups. By timed
matings of heterozygous mutant mice, we determined
that the genotypes of embryos showed Mendelian ratios
of inheritance up to E11.0, but no viable homozygous mu-
tants were obtained at later developmental time points
(Table S1).
HDAC7 mutant mice were indistinguishable from wild-
type embryos before E10.75. However, by E11.0, all
HDAC7 mutant embryos displayed widespread vascular
rupture, pericardial effusion, and enlarged dorsal aortae,
indicative of abnormalities in the circulatory system
(Figure 1C).
RT-PCR analysis of RNA from HDAC7mutant embryos
at E10.5 revealed that HDAC7 transcripts were absent in
homozygous mutants (Figures 1D and 1E). Transcripts
encoding other HDACs were expressed at normal levels
in mutant embryos (Figure 1F).
Endothelial Cell-Specific Expression of HDAC7
To begin to determine the cause of lethality inHDAC7mu-
tant embryos, we analyzed HDAC7 expression by in situ322 Cell 126, 321–334, July 28, 2006 ª2006 Elsevier Inc.hybridization. HDAC7 transcripts were first detected at
E9.5 in ECs within the heart and blood vessels and in mes-
enchyme (Figure 2Aa). At E11.0, HDAC7 expression was
restricted to ECs lining the vessels and endocardial cells
within the cardiac chambers (Figure 2Ab). At E15.5, ex-
pression of HDAC7 was also prominent in the myocardial
layer of the heart and in lung tissue (Figure 2Ac).
Mouse embryos harboring the HDAC7 mutation ex-
pressed lacZ in a pattern corresponding to that of the
endogenous HDAC7 gene. Cardiovascular specific ex-
pression of lacZ was observed at E9.5 (Figure 2Ba). At
E11.0, lacZ was predominantly expressed in large and
small vessels, arteries and veins, and the heart. Low ex-
pression in neural tube was also observed (Figure 2Bb).
Histologic sections of E11.0 embryos revealed that lacZ
expression was restricted to the ECs of the vasculature
and endocardial cells of the heart (Figures 2Ca–2Cf).
lacZ expression was not observed in myocardium at this
stage. lacZ staining of adult tissues from heterozygous
mutant mice showed that HDAC7 was highly expressed
in lung, heart, skeletal muscle, and vessels (data not
shown), consistent with the pattern of HDAC7 transcripts
detected by Northern blot (Kao et al., 2000). Histological
sections showed that lacZ was actually expressed specif-
ically in the ECs of the small vessels and capillaries within
these tissues. For instance, the ECs, but not the smooth
muscle cells (SMCs), of the ascending aorta strongly ex-
pressed lacZ (Figure 2Da); in the adult heart, lacZ was
highly expressed in the endocardial cells of the ventricles
and atria and in the small veins and capillaries amidst the
cardiac muscle fibers, but not in cardiomyocytes (Figures
2Db–2Dd). High lacZ expression was also observed in
capillaries of skeletal muscle and lung, while the skeletal
muscle fibers per se and the bronchi and alveoli did not
show lacZ staining (Figures 2De–2Df). HDAC7 expression
was undetectable in the yolk sac vasculature (data not
shown).
Cardiovascular Abnormalities in HDAC7
Mutant Mice
The dorsal aortae and cardinal veins were severely en-
larged and frequently ruptured, and there were fewer
than normal SMCs surrounding dorsal aortae in the
mutant embryos at E11.0 (Figure 3A). The branchial ar-
teries also were grossly enlarged, although not as severely
as the dorsal aortae (Figure 3B). In mutant embryos, right-
ward looping and chamber formation were normal, but the
myocardial walls of the ventricular chambers were abnor-
mally thin and atria were dilated (Figure 3A).
Electron microscopy showed tight junctions between
adjacent ECs in dorsal aortae and cardinal veins in wild-
type embryos, but such junctions were often missing
in mutant embryos prior to death (Figure 3C). Instead,
ECs appeared to extend processes that failed to establish
tight EC-cell interactions, which are essential for maintain-
ing vascular integrity. It was also noticeable that SMCs
attached well to ECs of the aorta in wild-type embryos,
while there were large intercellular spaces between ECs
Figure 1. Generation of HDAC7 Mutant Mice
(A) Strategy to generateHDAC7mutant mice by homologous recombination. Exons 2–5, which encode theMEF2 binding domain, were replaced with
a promoter-less nuclear lacZ cassette in-frame with exon 2 and a neomycin-resistance cassette.
(B) Southern blot analysis of genomic DNA from ES cells. DNA was digested with EcoRI; the positions of the wild-type (25 kb) and mutant (5.5 kb)
bands are indicated. Genotypes are shown on the top.
(C) Wild-type (left) and HDAC7mutant (right) embryos at E11.0. The HDAC7mutant showed dramatically enlarged dorsal aortae (arrow), pericardial
effusion (arrowhead), and hemorrhages (asterisk).
(D) Schematic of HDAC7 exons with positions of primers used for RT-PCR analysis.
(E) Analysis of HDAC7 transcripts by RT-PCR. Genotypes are shown on the top and primer pairs at the left.
(F) Transcripts for HDACs 1–6, 8, and 9 from embryos of indicated genotypes were analyzed by semiquantitative RT-PCR. GAPDH transcripts were
detected as a control.and surrounding SMCs in the mutant (Figures 3Ca and
3Cb).
Normal Differentiation and Patterning of Endothelial
and SMCs in HDAC7 Mutant Embryos
In light of the specific expression of HDAC7 in embryonic
ECsbyE11.0and theobviousmorphological abnormalities
in this cell population as revealed by electron microscopy,we examined for possible defects in EC differentiation in
HDAC7mutant embryos. A panel ofmolecularmarkers im-
portant for vasculogenesis, including VEGF, flk1, flt1, tie1,
tie2, Flt4, ET-1, ETA, Erb3, Neuregulin, ARNT, Hif1a, Hrt1,
Hrt2, Ang-1, Ang-2, endoglin-1, Smad5, LKLF, eNOS,
PDGFB, hb-EGF,and MEF2C, was analyzed either by
RT-PCR or RNA in situ hybridization, but no changes in
the expression levels of these genes were observedCell 126, 321–334, July 28, 2006 ª2006 Elsevier Inc. 323
Figure 2. Expression Pattern of HDAC7 during Mouse Embryogenesis and Adulthood
(A) HDAC7 transcripts were detected by RNA in situ hybridization to transverse sections as follows: (a) staining of ECs and surrounding mesenchyme
cells at E9.5, (b) staining of vascular endothelium and endocardium at E11.0, and (c) staining of heart, lung, andmajor vessels at E15.5. Here, h marks
the heart, la marks the left atrium, lu represents the lung, lv represents the left ventricle, ra shows the right atrium, and rv is the right ventricle.
(B) Expression of lacZ from targeted HDAC7 allele. (a), E9.5 and (b), E11.0.
(C) Light eosin staining of histological sections of HDAC7+/ embryos at E11.0 prestained for lacZ. Arrows point to ECs stained for b-galactosidase
expression. Shown are (a) communication between dorsal aorta and branchial arch arteries, (b) the endocardium, (c) the third branchial arch artery,
(d) the outflow tract, (e) a small vessel in the head, and (f) an intersomitic vessel.
(D) Expression of lacZ from targeted HDAC7 allele in adult tissues. Arrows point to ECs stained for b-galactosidase expression. Shown are (a)the
ascending dorsal aorta, (b) the endocardium of ventricle, (c) endocardium of atria, (d) the small vessels and capillaries within the myocardium,
(e) small vessels and capillaries within skeletal muscle, and (f) an artery and capillaries of the lung.(Figure 4A and data not shown). Among these genes, tie1,
tie2,Ang-1, andAng-2 are involved in recruitment of SMCs
by ECs (Thurston, 2003).
To visualize the primitive vasculature plexus, we stained
E10.5 embryos with an antibody against PECAM, an EC-
specific marker. As shown in Figures 4Ba–4Bh, differenti-
ated ECswere properly positioned in themutant embryos.
The complexity and patterning of the cranial vasculature,
the intersomitic vasculature, and the dorsal aortae as re-
vealed by PECAM staining were also similar in wild-type
and HDAC7 mutant embryos. Transverse sections
showed the presence of ECs in the dorsal aortae and324 Cell 126, 321–334, July 28, 2006 ª2006 Elsevier Inc.cardinal veins in both wild-type and HDAC7 mutant em-
bryos, although the vessels in the mutant embryos were
larger than normal. Similarly, PECAM staining was de-
tected in the endocardium of wild-type and mutant
embryos (Figure 4C). These results indicated that EC dif-
ferentiation and patterning were unaffected by disruption
of the HDAC7 gene.
Recruitment of SMCs by arterial ECs provides contrac-
tility and mechanical support for the developing arteries.
To investigate whether the vascular abnormalities in
HDAC7 mutant embryos were caused by a defect in
recruitment or differentiation of SMCs, we performed
Figure 3. Cardiovascular Defects in HDAC7 Mutant Mice
(A) Histological analysis of HDAC7 mutant mice. (a–c) Shown are low magnifications of H&E staining of transverse sections from E11.0 embryos of
indicated genotypes; panel (b) shows anHDAC7mutant embryo at the onset of the phenotype, and panel (c) shows another embryo a few hours later
after complete vascular demise. Note dilated vessels in HDAC7 mutants. (d–f) Shown is high magnification of the dorsal aortae. Note that there are
fewer supporting cells in mutant embryos (arrows). Shown are the cardinal vein (cv), dorsal aorta (da), la, left atrium (la), left ventricle (lv), right atrium
(ra), and right ventricle (rv).
(B) Sections showing dilated branchial arch arteries 3, 4, and 6 in the HDAC7 mutant (arrows).
(C) Electron microscopy of the blood vessels (aorta, a–d; vein, e–h) ofHDAC7mutant embryos. EC-cell adhesions were perturbed in mutant sections.
Boxes in panels (a), (b), (e), and (f) are enlarged in (c), (d), (g), and (h). Arrows in panels (c) and (g) point to tight junction in the wild-type embryo. Arrows
in panels (b) and (f) point to abnormal EC extension in the mutant embryo. The SMCs are tightly connected to the ECs in the wild-type aorta, while this
connection is disrupted in the mutant (panels a and b, arrowheads).whole-mount antibody staining for smooth muscle (SM) a-
actin. Normal patterning of SMCs was observed in mutant
embryos, suggesting that vascular ECs were capable of
recruiting SMCs. However, the staining of SM a-actin in
the dorsal aorta was less prominent in the mutant than
normal (Figures 4Da–4Df). Immunostaining against Ephrin
B, an arterial-specific EC marker, confirmed that SMCs in
the dorsal aorta in the mutant embryos correctly adopted
the arterial fate (data not shown). However, fewer SM a-
actin-positive cells were observed in mutant compared
to wild-type embryos (arrowheads in Figures 4De–4Df),
suggesting a possible abnormality in recruitment ofSMCs by ECs in the absence of HDAC7. TUNEL staining
showed no difference in apoptosis in endothelial and
SMC populations between wild-type and mutant embryos
(data not shown). We conclude that the absence of
HDAC7 results in a specific abnormality in EC-cell adhe-
sion and recruitment of SMCs with consequent vascular
rupture and embryonic death.
EC-Specific Deletion of HDAC7
To confirm that HDAC7 acted cell autonomously within
ECs to control vascular integrity, we generated mice
bearing a conditional HDAC7 null allele, referred to asCell 126, 321–334, July 28, 2006 ª2006 Elsevier Inc. 325
Figure 4. Normal Endothelial and SMC Differentiation in HDAC7 Mutant Embryos
(A) Several genes important for vasculogenesis, including tie1, tie2, and flk1, are expressed normally inHDAC7mutant embryos, shown by RNA in situ
hybridization.
(B) Whole-mount PECAM staining of wild-type (a) and mutant (e) embryos at E10.5. The vascular plexus is well formed in mutant mice. (b–d, f–h) High
magnification shows the complexity of the vascular network in both wild-type and HDAC7 mutant embryos.
(C) Histological sections showing enlarged dorsal aorta (da) defined by PECAM staining in HDAC7 mutant embryos. Here, h marks the heart and nt
marks the neural tube.
(D) Immunostaining for SM a-actin. (a and b) SM a-actin staining of embryos at E11.0 are shown. Staining of the dorsal aorta in mutant embryos (ar-
rows) is less prominent than in wild-type embryos (c and d). Transverse sections of wild-type andmutant embryoswere stained for SM a-actin (green).
(e and f) High magnification of dorsal aorta shows dilatation and reduced staining with a thinner pattern in mutant embryos (arrows). Nuclei were
stained with DAPI (blue).HDAC7flox, flanked by loxP sites for deletion by Cre re-
combinase (Figure 5A). The targeting strategy introduced
loxP sites in introns 1 and 10, such that Cre-mediated re-
combination would result in the deletion of residues 1–435
of the N-terminal domain of the protein (Figure 5B). ES cell
clones heterozygous for the HDAC7flox mutation were
used to generate chimeric mice. Transmission of the326 Cell 126, 321–334, July 28, 2006 ª2006 Elsevier Inc.conditional allele from male chimeras through the germ-
line was confirmed by PCR analysis (Figure 5B). The mu-
tation introduced a neomycin resistance cassette, which
was removed in the germline by crossing with FLPe
animals (Figure 5A).
Mice homozygous for the HDAC7flox allele were pheno-
typically normal, indicating that the presence of the loxP
sites in the gene did not disrupt HDAC7 expression. To
achieve conditional deletion of HDAC7, Tie2-Cre;
HDAC7+/ or aMHC-Cre;HDAC7+/ mice were bred with
mice homozygous for the HDAC7flox allele. Introduction
of a Cre recombinase transgene controlled by the endo-
thelial-specific promoter of the Tie2 gene (Kisanuki et al.,
2001) resulted in embryonic lethality at E11.5 and cardio-
vascular abnormalities similar to those of HDAC7 knock-
out mice (Figure 5C). As was observed with the global
deletion, the lethal phenotype resulting from endothelial-
specific HDAC7 gene deletion was 100% penetrant. Aor-
tic enlargement was more moderate than in the null ani-
mals. However, the conditional deletion displayed all of
the cardiovascular features seen in the nulls, including
a reduction in arterial SMC numbers, endothelial elonga-
tion, multifocal hemorrhages, edema, and myocardial
thinning. In contrast, HDAC7flox/KO mice bearing a Cre
transgene controlled by the a-myosin heavy chain pro-
moter, which directs expression in cardiomyocytes,
were viable (data not shown). We conclude that HDAC7
is required specifically in embryonic ECs for cell-cell
adhesion and maintenance of vascular integrity.
Altered Gene Expression by Knockdown of HDAC7
in ECs In Vitro
In an effort to identify potential HDAC7 target genes in ECs
thatmight reveal themechanismbywhichHDAC7controls
vascular integrity, we used RNAi to suppress HDAC7
expression in Human Umbilical Vein ECs (HUVECs). In
HUVECs transfected with siRNA specific for HDAC7
mRNA, HDAC7 transcripts were downregulated at least
70% compared to controls as confirmed by immuno-
staining (Figure 6A).
When cultured on matri-gel, HUVECs spontaneously
organize into a primitive vascular network. In the presence
of HDAC7 siRNA, HUVECs failed to adhere to each other
and instead remained as single cells or clumps of cells
(Figure 6Bb). In contrast, GFP siRNA, as a control, had
no effect on the ability of HUVECs to become organized
into an endothelial lattice (Figure 6Ba).
Microarray analysis to compare the gene expression
profiles of HUVECs treated with HDAC7 siRNA and con-
trols revealed that numerous genes encoding extracellular
matrix and adhesion proteins were dysregulated in the
presence of HDAC7 siRNA (Table S2). Of particular inter-
est were the genes encoding matrix metalloproteinase 10
(MMP10), also referred to as stromelysin 2, which was up-
regulated by 6.5-fold, and its inhibitor tissue inhibitor of
metalloproteinase 1 (TIMP1), which was downregulated
by 8.6-fold. MMP10 is a secreted proteinase that de-
grades the extracellularmatrix, and TIMP1 inhibitsMMP10
activity (Rundhaug, 2005; Yoon et al., 2003). Thus, the up-
regulation of MMP10 and concomitant downregulation of
TIMP1 would be predicted to disrupt cell-cell adhesion
and perturb vascular integrity in HDAC7mutant embryos.
The changes in expression of these genes in HUVECs
treated with siRNA targeted to HDAC7 were validated by
RT-PCR (Figure 6C).Consistent with the potential involvement of MMP10 in
endothelial abnormalities associated with loss of HDAC7
function, adenoviral-mediated misexpression of MMP10
in cultured HUVECs impaired the angiogenic ability of
HUVECs, although the defect was not as dramatic as
the effect of HDAC7 RNAi (Figure 6Bd). Treatment of EC
cultures with TIMP1 siRNA caused a similar loss of adhe-
siveness (Figure 6Bc). The combined effect of TIMP1
knockdown and MMP10 overexpression was very similar
to the effect of HDAC7 knockdown (Figure 6Be), indicating
that it is very likely that MMP10 and TIMP1 are involved in
the regulation of vascular integrity by HDAC7. Gene ex-
pression changes were confirmed by RT-PCR (Figure 6C).
We further examined the expression of MMP10 and
TIMP1 in HDAC7 mutant embryos by immunohistochem-
istry. Consistent with their expression in cultured ECs,
MMP10 was dramatically upregulated in the perivascular
region, while TIMP1 was downregulated in vascular ECs
inmutant embryos (Figure 6D). The diffuse staining pattern
of these proteins in the perivascular region reflects the
fact that they are secreted.
MMP10 Is a Direct Target of MEF2 and HDAC7
Given the fact that HDAC7 is a transcriptional repressor
and MMP10 is upregulated in HDAC7 mutant embryos,
we searched for evolutionarily conserved sequences in
the upstream region of theMMP10 gene thatmight control
expression of MMP10 in ECs. Two AP-1 sites and two
PEA3 sites in the MMP10 promoter are responsible for
constitutive expression and induction by inflammation
(Chakraborti et al., 2003).
We identified a potential MEF2 site in the MMP10 pro-
moter, and DNA binding assays using extracts from
COS cells transfected with a Myc-MEF2C expression
plasmid confirmed that this site was a bona fide binding
site for MEF2 (Figure 7A). TheMEF2-consensus sequence
from the MMP10 promoter bound MEF2C comparably to
the canonical MEF2 site from the muscle creatine kinase
(MCK) enhancer (Gossett et al., 1989) (Figure 7B). This
DNA-protein complex was super-shifted by anti-Myc anti-
body and was abolished in the presence of an excess of
the unlabeled cognate DNA sequence or the MCK MEF2
site as a competitor, whereas a mutant sequence failed
to compete for MEF2C binding (Figure 7B). Similarly, the
DNA-protein complex between MEF2 and the MCK
MEF2 site was abolished by an excess of unlabeled
MCK MEF2 sequence or MMP10 MEF2 sequence but
not by the mutant sequence (Figure 7B).
A DNA fragment containing theMMP10MEF2 site con-
ferred MEF2 responsiveness to a luciferase reporter in
transfected COS cells, and mutation of the MEF2 site
completely abolished responsiveness to MEF2 (Fig-
ure 7C). Moreover, HDAC7 prevented activation of the
MMP10 promoter by MEF2. A mutant of HDAC7 lacking
the MEF2 binding domain (HDAC7-DMEF) failed to inhibit
the MMP10 promoter, whereas a mutant lacking the sig-
nal-responsive serines (HDAC7-S/A), which functions asCell 126, 321–334, July 28, 2006 ª2006 Elsevier Inc. 327
Figure 5. EC-Specific Deletion of HDAC7
(A) Strategy to generate a conditional HDAC7 mutant allele. loxP sites were inserted into introns 1 and 10. The structures of the genomic locus, the
targeting vector, and the targeted allele are shown. The neomycin resistance cassette, flanked by FRT sites, was removed in the mouse germline by
breeding heterozygous mice to hACTB::FLPe transgenic mice. Endothelial-specific deletion ofHDAC7was achieved by breeding to transgenic mice
harboring a Tie2-Cre transgene. Positions of probes used for Southern analysis and primers used for PCR are shown.
(B) Genotyping of HDAC7mutant mice. Primers flanking the 50 loxP site as well as the 50 end of the lacZ insertion generate PCR products as shown in
panel A. Lane 1 shows wild-type, lane 2 shows HDAC7, lane 3 shows HDAC7loxP, and lane 4 shows HDAC7loxP.328 Cell 126, 321–334, July 28, 2006 ª2006 Elsevier Inc.
Figure 6. Effect of HDAC7 on MMP10 and TIMP1 Expression in ECs
(A) Immunocytochemistry against HDAC7 in HUVECs. HDAC7 protein level was significantly downregulated by siRNA transfection.
(B) In vitro angiogenesis assay. HUVECs failed to form a vascular network after HDAC7 knockdown (b). The angiogenic activity of HUVECs was also
significantly impaired by either TIMP1 knockdown or MMP10 overexpression (c and d), the combination of which mimics the effect of HDAC7 knock-
down (e). The control was infected with GFP adenovirus 2 days after GFP siRNA treatment, and the cells were cultured for an additional 2 days before
the in vitro angiogenesis assay.
(C) RT-PCR analysis to confirm microarray data. RNAi knockdown of HDAC7/TIMP1 and overexpression of MMP10 were also confirmed. At least
70% of HDAC7/TIMP1 transcripts were eliminated by siRNA transfection.
(D) Immunohistochemistry against MMP10 and TIMP1. Note that MMP10 is upregulated (arrows) and TIMP1 is downregulated (arrows) in the endo-
thelium of the dorsal aorta of HDAC7 mutant embryos. Nuclei were stained with DAPI (blue).a ‘‘super-repressor, ’’ showed greater repressive activity
against MEF2 (Figure 7D).
To further validate the association of MEF2C with the
MMP10 promoter, we performed chromatin immunopre-cipitation (ChIP) assays. As shown in Figure 7E, MEF2,
which is expressed in and required for EC differentiation
(Lin et al., 1997, 1998), was detected on the MMP10 pro-
moter in the context of native chromatin in Human Aortic(C) Wild-type (top panels) and HDAC7flox/KO; Tie2-cre mutant (bottom panels) embryos at E11.5. Panels (a) and (b) show whole embryos. Diffuse
edema around the neural tube and hepatic vascular congestion can be seen in the mutant. Panels (c) and (d) show transverse sections. Boxes
show regions of the heart expanded in panels (e) and (f). Arrows point to the myocardial cell layer, which is hypocellular in the mutant. Panels (g)
and (h) show dorsal aortae. Discontinuity of the SMC layer and endothelial elongation are present in the mutant (arrowheads).Cell 126, 321–334, July 28, 2006 ª2006 Elsevier Inc. 329
Figure 7. MMP10 Expression is Controlled by MEF2 and HDAC7
(A) The sequence of the mouse MMP10 gene containing the potential MEF2 site is shown.
(B) Gel mobility shift assays were performed with a labeled MMP10 probe or MCK probe and extracts from COS cells overexpressing Myc-MEF2C.
Unlabeled MMP10 probe and MCK probe were indistinguishable in their ability to compete with labeled probes to form a DNA-protein complex. The
DNA-protein complex was supershifted in the presence of an anti-myc antibody.330 Cell 126, 321–334, July 28, 2006 ª2006 Elsevier Inc.
ECs (HAECs). In addition, endogenous HDAC7 and the
HATs CBP and p300 were detected on the MMP10 pro-
moter, which suggests that the balance of HDAC and
HAT activity at the promoter plays a critical role in control-
ling the expression of MMP10. We conclude that MEF2
binds directly to the regulatory region responsible for ex-
pression of MMP10 in ECs and that HDAC7 and HATs
are recruited byMEF2 to theMMP10 genewhere they reg-
ulate MMP10 expression antagonistically.
To further explore the potential influence of histone
acetylation/deacetylation on MMP10 expression, we in-
fected HAEC cultures with an adenovirus encoding a
signal-resistant HDAC5 mutant, which, like HDAC7, re-
presses MEF2 activity (McKinsey et al., 2000a). As shown
in Figure 7F, cultures infected with Ad-Flag-HDAC5
showed a reduction in expression of MMP10 expression,
as detected by RT-PCR. Association of Flag-HDAC5 with
the MMP10 promoter was confirmed by ChIP assay and
was accompanied by a decrease in acetylated histone
H3 on the promoter detected by ChIP assay with Acetyl-
H3 antibody. In contrast, we detected no change in acet-
ylation of the glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) gene, which is not regulated by class II
HDACs. These findings support the conclusion that re-
cruitment of HDAC7 to the MMP10 promoter by MEF2
represses MMP10 expression, whereas loss of HDAC7
activates MMP10 expression.
DISCUSSION
The results of this study reveal a key role of HDAC7 in
maintenance of vascular integrity. Disruption of the
HDAC7 gene, which is expressed specifically in ECs, re-
sults in embryonic lethality by E11.0 due to cardiovascular
defects that include dilated and ruptured blood vessels,
dilated atria, and thin-walled myocardium. ECs of
HDAC7 mutant embryos appear normal during initial dif-
ferentiation and patterning but display cell-cell adhesion
defects accompanied by upregulation of MMP10. Pro-
moter analysis revealed that MMP10 is a direct target of
MEF2, a key transcription factor required for EC differen-
tiation, suggesting that HDAC7 regulates vascular perme-
ability, at least in part by modulating MMP10 expressionthrough inhibiting MEF2 activity, as schematized in
Figure 7G.
Regulation of Vascular Integrity by HDAC7
Formation of the vasculature involves two sequential
steps: vasculogenesis, the initial formation of a primary
vascular plexus, and angiogenesis, a process of sprouting
or splitting of blood vessels and remodeling of vascular
beds (Cleaver and Krieg, 1999). During both processes,
ECs recruit supporting cells, SMCs in major arteries, and
pericytes in microvessels to provide contractility and me-
chanical support.
The primary defect in HDAC7 mutant embryos is the
loss of vascular integrity with consequent embryonic de-
mise. Formation of the primary vascular plexus—vasculo-
genesis, which begins at E7.5 in mice—is unperturbed in
HDAC7 mutant embryos. At E9.5, when HDAC7 expres-
sion is first detectable in the vascular endothelium, recruit-
ment of the first layer of SMCs is essentially complete,
which explains why perivascular SM a-actin staining is de-
tected inHDAC7mutant embryos. However, by E11.0, the
ability of ECs in HDAC7 mutant embryos to recruit sup-
porting cells appears to be compromised, as evidenced
by perivascular hypocellularity in the mutants and associ-
ated loss of EC-cell adhesion. We postulate that the onset
of vascular disruption in HDAC7 mutant embryos reflects
the dissolution of EC-cell interactions, as the weakened
vessel wall can no longer withstand the increasing hemo-
dynamic pressure from the ever-increasing activity of the
heart. The finding that EC-specific deletion of HDAC7 re-
sults in the same phenotype as global deletion of the gene
confirms the specific requirement of HDAC7 in the devel-
oping vascular endothelium.
Vascular integrity is maintained by tight junctions be-
tween adjacent ECs, which form the seamless inner lining
of blood vessels. During angiogenesis, MMPs degrade
components of the extracellular matrix including the junc-
tional complex, which facilitates detachment of support-
ing cells and permits ECs to migrate into surrounding
tissues (Rundhaug, 2005; Yoon et al., 2003). MMP10 has
been shown to activate other MMPs, such as MMP1,
with consequent acceleration of capillary tube regression
of ECs in vitro (Saunders et al., 2005). TIMPs, which(C) Responsiveness of MMP10 gene promoter to MEF2. COS-1 cells were transfected with pGL3-Luc reporter containing the region from 886 bp
to +11 bp of the MMP10 gene with indicated amounts of MEF2D. Mutation of the predicted MEF2 site completely abolished the responsiveness of
the MMP10 promoter to MEF2D. Values represent the mean ± standard deviation (SD).
(D) Activation ofMMP10 promoter by MEF2 is inhibited by wild-type HDAC7 and signal-resistant HDAC7 mutant (HDAC7-S/A) but not by an HDAC7
mutant lacking the MEF2 binding domain (HDAC7-DMEF). Values represent the mean ± standard deviation (SD).
(E) ChIP assays were performed with chromatin prepared from HAECs. Chromatin was immunoprecipitated with mouse IgG or antibodies against
acetylated histone H3, MEF2, HDAC7, CBP, or p300, and precipitated genomic DNA was analyzed by PCR using primers for theMMP10 promoter,
which contains an MEF2 binding site. PCR amplification was performed prior to immunoprecipitation for the input control.
(F) HAECs were infected with adenovirus encoding either GFP or a constitutively nuclear form of HDAC tagged with Flag epitope. ChIP and RT-PCR
analysis were performed 48 hr after infection. HDAC was detected on the MMP10 promoter region, which resulted in hypo-acetylation of the pro-
moter, and consequently MMP10mRNA expression was reduced when HDACwas overexpressed. In contrast, there was no change in histone acet-
ylation at the GAPDH promoter in response to HDAC overexpression, demonstrating the specificity of this response for MMP10.
(G) A model for modulation of MMPs by HDAC7 through inhibition of MEF2 activity. MMP10 expression is controlled by MEF2, which is antagonized
by HDAC7 in ECs. In the absence of HDAC7, MMP10 is overexpressed. Combined with downregulation of TIMP1, the extracellular matrix is greatly
disrupted, which leads to dilatation and rupture of blood vessels.Cell 126, 321–334, July 28, 2006 ª2006 Elsevier Inc. 331
represent a family of endogenous MMP inhibitors, are
highly expressed in ECs and provide native protection
from breakdown of the endothelium (Handsley and Ed-
wards, 2005). The upregulation of MMP10 was accompa-
nied by downregulation of its inhibitor TIMP1, which would
be expected to further exacerbate the abnormalities in
vascular integrity.
Regulation of MMP10 by MEF2 and HDAC7
during Endothelial Development
MEF2C is highly expressed in the developing vascular en-
dothelium, and MEF2C knockout mice die at E9.5 from
vascular abnormalities that have been attributed in part
to endothelial defects (Lin et al., 1997, 1998). MEF2 serves
as a platform for the mutually exclusive recruitment of
class II HDACs or p300 (Youn et al., 2000; Youn and Liu,
2000). Class II HDACs, including HDAC7, contain a short
peptide sequence near their N termini that tethers them
to MEF2, resulting in repression of MEF2 target genes
such as MMP10. Signaling pathways involving G pro-
tein-coupled receptors and calcium-dependent protein
kinases lead to the phosphorylation of serine residues in
the N-terminal regulatory domains of class II HDACs
(Chang et al., 2005; Dressel, et al., 2001; McKinsey
et al., 2000a, 2000b; Vega et al., 2004a).When phosphory-
lated, these sites bind 14-3-3 chaperone proteins, which
escort class II HDACs from the nucleus to the cytoplasm,
freeing MEF2 from the repressive influence of class II
HDACs (McKinsey et al., 2000b) and allowing p300 to
dock on MEF2 and stimulate MEF2-dependent transcrip-
tion. Our results show that HDAC7 potently represses the
MMP10 promoter, whereas amutant form of HDAC7 lack-
ing the MEF2 binding domain is unable to repressMMP10
transcription. By ChIP assays, we detected HDAC7 and
p300/CBP on the MMP10 promoter, suggesting that the
activity of the promoter is dependent on a balance be-
tween the positive and negative influences of these
MEF2 cofactors, respectively. Class I HDACs have also
been implicated in the regulation of extracellular matrix
proteins including MMPs through unknown mechanisms
(Whetstine et al., 2005), and HDAC inhibitors regulate
MMP activity by inducing the expression of RECK, a re-
pressor of MMPs (Ailenberg and Silverman, 2002; Chang
et al., 2004a; Liu et al., 2003b).
Implications
The realization that HDAC7 regulates MMP10 expression
and vascular integrity has potentially important implica-
tions for a variety of human disorders. Vascular leakage
causes circulatory collapse and contributes to the patho-
genesis of numerous, usually life-threatening diseases
such as atherosclerosis and aneurysms. The balance be-
tweenMMP and TIMP activity is critical for maintaining the
integrity of the cardiovascular system. The upregulation of
MMP10 and concomitant downregulation of TIMP1 ex-
pression observed in HDAC7 mutant embryos is reminis-
cent of the change in expression of these two families of
antagonistic proteins in multiple cardiovascular disorders.332 Cell 126, 321–334, July 28, 2006 ª2006 Elsevier Inc.Following myocardial infarction, for example, MMP9
expression is upregulated, while TIMP1 expression is
downregulated (Cleutjens and Creemers, 2002; Creemers
et al., 2001). Heart failure and ventricular dilatation is asso-
ciated with similar changes in expression of MMPs and
TIMPs (Spinale, 2002). The imbalance between these
opposing proteins has been implicated in pathological
remodeling of the myocardium and has pointed to the
potential usefulness of MMP inhibitors in restoration of
cardiac function in these disorders (Creemers et al.,
2003). The mechanisms responsible for the dysregulation
of MMP and TIMP expression in these disorders have not
been defined.
MMP10 and TIMP1 have been shown to be associated
with aortic aneurysm, characterized by destructive re-
modeling of the vascular extracellular matrix and rupture
of the vessel wall, and are likely to contribute to disease
pathogenesis (Ogata et al., 2005a). Thus, strategies to
suppress MMP10 expression and maintain TIMP expres-
sion by maintaining HDAC7 activity would be predicted to
have therapeutic value.
Tumor angiogenesis is also an essential step in metas-
tasis that requires formation of a stable endothelial plexus.
MMP inhibitors as well as HDAC inhibitors have been used
to prevent metastasis and treat cancer (Ailenberg and Sil-
verman, 2002; Kim et al., 2000; Liu et al., 2003a, 2003b;
London et al., 2003; Ogata et al., 2005b). We predict
that inhibition of HDAC7 activity in tumors and consequent
upregulation of MMPs would also have antiangiogenic
consequences and eventually lead to regression of tumors
due to the disruption of vascular supply. Hence, these
findings point to HDAC7 as a potential therapeutic target
for vascular-related disorders including heart failure, aor-
tic aneurysm, and tumorigenesis.
EXPERIMENTAL PROCEDURES
Generation of HDAC7 Mutant Mice
BothHDAC7KO andHDAC7loxP alleles were generated by homologous
recombination in ES cells. Targeted ES cells carrying each disrupted
allele were injected to E3.5 C57BL/6 mouse blastocysts to produce
chimeric mice. Chimeras were mated with C57BL/6 females to obtain
F1 mice carrying the targeted allele. For detailed procedures, please
see Supplemental Data.
RNA In Situ Hybridization and Histology
Embryos and tissues used for histology were fixed in 4% paraformal-
dehyde, sectioned, and processed for hematoxylin and eosin (H&E)
staining or in situ hybridization by using standard procedures (Shelton
et al., 2000). 35S-labeled RNA probes were generated usingMaxiscript
kit (Amersham). Signals were pseudocolored in red using Adobe
Photoshop.
RT-PCR and Microarray Analysis
Total RNA was extracted from embryos or HUVECs using Trizol re-
agent (Invitrogen) and used as a template for reverse transcriptase
with random hexamer primers (Invitrogen). Primer sequences for spe-
cific genes are available upon request. Microarray analysis was per-
formed using Human Genome U133 Plus 2.0 array (Affymetrix).
Whole-Mount Staining and Immunohistochemistry
Immunostaining of embryos was performed as described previously
(Li et al., 2003). Briefly, embryos were fixed in 4% paraformaldehyde,
bleached with 5% H2O2, blocked in 3% milk, incubated with primary
antibodies and second antibody sequentially, and, finally, stained
with the DAB kit (Vector labs). Antibodies used were anti-mouse
CD31 (clone MEC13.3, Pharmingen), anti-SM a-actin (Clone 1A4,
Sigma), anti-MMP10 (clone IVC5, Chemicon), anti-TIMP1 (polyclonal,
Chemicon), and HRP-conjugated goat anti-rat IgG (Jackson Immu-
noResearch). b-galactosidase staining of embryos and tissues was
performed as described (Cheng et al., 1993). After staining, samples
were sectioned and counterstained with light eosin.
Electron Microscopy
Wild-type andHDAC7mutant embryos were fixed overnight in 2%glu-
taraldehyde in 0.1 M cacodylate buffer at 4C and then postfixed and
dehydrated in an ethanol series. Samples were then embedded in
Spurr resin (Ted Pella, Inc., Redding, CA), stained with uranyl acetate
and lead citrate, and sectioned at 80 nm as described (Li et al., 2005).
Cell Culture and Immunocytochemistry
HUVEC cells were purchased from ATCC. HAEC cells were obtained
from Clonetics. Both cell lines were cultured in EC growth medium
(Clonetics/Cambrex). For immunostaining, cells were plated on gela-
tin-coated glass coverslips and were fixed and stained as described
(McKinsey et al., 2000a). HDAC7 antibody was purchased from Santa
Cruz.
RNAi, Adenovirus Infection, and In Vitro Angiogenesis
SiRNA oligonucleotides for HDAC7 were purchased from Ambion and
used at a concentration of 40 nM. SiRNA oligonucleotides for TIMP1
were purchased from Dharmacon and used a concentration of
70 nM. HUVECs were transfected with Liptofectamine Plus reagent
(Invitrogen). Four days after transfection, cells were harvested either
for RNA analysis or in vitro angiogenesis. Adenovirus encoding human
MMP10 (Saunders, et al., 2005) was generously provided by Dr.
George E. Davis (Texas A&M University). HUVECs were infected with
either GFP or MMP10 adenovirus 2 days after RNAi transfection, and
cells were harvested 2 days later. Matri-gel was purchased from
Chemicon, and the assays were performed as instructed by the man-
ufacturer. RT-PCR and in vitro angiogenesis were performed multiple
times with comparable results. PCR primer sequences are available
upon request. HDAC7-siRNA sequence is the following: TCACTG
ACCTCGCCTTCAA.
Reporter Assays
TheMMP10-luciferase construct contained aDNA fragment extending
from 886 bp to +11 bp of the mouse MMP10 gene. The N-terminal
flag-tagged HDAC7 and HDAC7 mutants were subcloned into
pcDNA3.1 vector (Invitrogen). Amino acids 76–130 were deleted in
the HDAC7-DMEFmutant. MEF2D and myc-tagged MEF2C were pre-
viously described (Phan et al., 2005). COS cells in 24-well plates were
transfected with 150 ng of reporter plasmids in the presence or ab-
sence of MEF2D or HDAC7. The reporter assays were performed as
described (Chang et al., 2005).
Gel Mobility Shift Assay
Gel mobility shift assays were performed as described (Chang et al.,
2001). COS cells were lysed 48 hr after transfection with a myc-tagged
MEF2C expression plasmid or empty vector. The DNA probe was la-
beled with 32P-dCTP using a Klenow fill-in method and purified using
a G25 DNA purification column from Roche. The 20 ml binding reaction
contained 1 mg of poly (dI-dC) (Sigma), 50,000 cpmof probe, and 2 ml of
cell lysate. After incubation at room temperature for 15 min, the reac-
tions were separated on a 5% PAGE gel containing 0.5 3 TBE.Chromatin Immunoprecipitation Assay
A ChIP kit was used for the assays according to manufacturer’s in-
structions (Upstate Biotechnology). Acetyl-histone3 antibody was
purchased from Upstate Biotechnology and MEF2 antibody was pur-
chased from Santa Cruz. HDAC7 antibody and CBP antibodies were
purchased from Abcam, and p300 antibody was purchased from
Santa Cruz. Primer sequences are available upon request. Adenovirus
encoding HDAC5 with alanine substitutions for serines 259 and 498
(S259/498A) was described previously (McKinsey et al., 2000a).
Supplemental Data
Supplemental Data include two tables and some experimental proce-
dures and references and can be found with this article online at http://
www.cell.com/cgi/content/full/126/2/321/DC1/.
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